What is galectin-3?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 30, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

What is Galectin-3?

Galectin-3 (Gal-3) is a β-galactoside-binding lectin that functions as a biomarker of inflammation and cardiac fibrosis, particularly in heart failure, where it drives pathological remodeling by inducing fibroblast proliferation and collagen deposition. 1

Molecular Structure and Classification

Galectin-3 is a 31 kDa protein and the only chimeric member of the galectin family, containing:

  • A C-terminal carbohydrate-recognition domain (CRD) that binds β-galactosides
  • An N-terminal protein-binding domain
  • This unique structure distinguishes it from all other galectins 2, 3

Cellular Location and Secretion

The protein exhibits remarkable versatility in its cellular distribution:

  • Predominantly cytoplasmic
  • Shuttles into the nucleus
  • Appears on cell surfaces
  • Secreted into biological fluids (serum, urine) through a non-classical pathway that bypasses the endoplasmic reticulum/Golgi network 4, 3

Pathophysiological Mechanisms

In Heart Failure

Galectin-3 serves as a marker of inflammatory response with direct pathological effects 1:

  • Expression increases in activated macrophages
  • Interacts with cardiac proteins and molecules to stimulate pathological remodeling
  • Specifically induces fibroblast proliferation and collagen deposition
  • This mechanism drives the progression of both heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF) 1

Broader Inflammatory and Fibrotic Roles

Beyond cardiac disease, Gal-3 is a key player in 5, 6:

  • Hepatic, renal, and pulmonary fibrosis
  • Chronic inflammation
  • Angiogenesis
  • Atherosclerosis and plaque instability
  • Tissue repair processes

Clinical Applications as a Biomarker

Diagnostic Utility

In heart failure patients, elevated Gal-3 levels 1:

  • Support diagnosis in both HFrEF and HFpEF
  • Correlate modestly with mortality risk
  • Show weaker prognostic association compared to natriuretic peptides or sST2 in chronic ambulatory heart failure 1

Therapeutic Implications

A notable finding from the CORONA trial suggests that patients with Gal-3 levels below the median (19.0 ng/mL) may benefit from statin therapy, raising the hypothesis that Gal-3 could identify subgroups responsive to specific treatments 1

Immune System Functions

Galectin-3 plays dual roles in innate immunity 2:

  • Functions as a pattern-recognition receptor (PRR) that directly binds pathogens
  • Acts as a danger-associated molecular pattern (DAMP) signaling tissue damage
  • Modulates functions of innate immune cells
  • Participates in host defense against invading microorganisms

Emerging Therapeutic Target

The protein's involvement in multiple disease pathways has generated pharmaceutical interest 5, 7:

  • New-generation Gal-3 inhibitors with improved potency, selectivity, and bioavailability are in development
  • Preclinical models show promise in preventing cardiac inflammation and fibrosis
  • Clinical trials are investigating Gal-3 inhibition for organ fibrosis and inflammatory conditions

Important Caveats

While Gal-3 shows promise as a biomarker, clinicians should recognize:

  • Its prognostic value in chronic heart failure is less robust than other established biomarkers like natriuretic peptides 1
  • The protein exhibits pleiotropic effects across multiple biological systems, making interpretation complex
  • Serial measurements may provide more clinical value than single time-point assessments

References

3
Research

Galectin-3 as a multifunctional protein.

Cellular & molecular biology letters, 2004

5
Research

Targeting galectin-3 in inflammatory and fibrotic diseases.

Trends in pharmacological sciences, 2023

6
Research

Galectin-3 in Cardiovascular Diseases.

International journal of molecular sciences, 2020

Related Questions

What does a galectin‑3 level of 36.4 ng/mL indicate and how should it be managed?
How can I lower my galectin‑3 level?
How should a flexor tendon injury be evaluated and managed?
What are the treatment recommendations for a patient with a right lower extremity moderate focal stenosis, a proximal common iliac artery mural thrombus, moderate multifocal stenosis of the superficial femoral artery, a moderate‑severe focal stenosis in the adductor canal, a peripheral mural thrombus, and a penetrating ulcer?
What is the recommended evaluation and management for a patient with loss of flexion of the ring finger after it was caught in a shirt, suggesting possible flexor tendon injury?
What immediate conservative management plan should be recommended for a patient with right‑side temporomandibular joint (TMJ) muscle spasm causing recurrent jaw locking, pain behind the ear, bruxism, and intolerance to mouth guards?
What empiric antibiotic regimen is recommended for an adult burn patient with suspected infection?
What does a galectin‑3 level of 36.4 ng/mL indicate and how should it be managed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.